147 related articles for article (PubMed ID: 38170552)
1. Updates in the treatment of HR+HER2- breast cancer.
Baclig NV; McCann KE
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):57-63. PubMed ID: 38170552
[TBL] [Abstract][Full Text] [Related]
2. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.
Patterson-Lomba O; Dalal AA; Ayyagari R; Liu O; Dervishi E; Platt E; Chandiwana D; O'Shaughnessy JA
Breast J; 2019 Sep; 25(5):880-888. PubMed ID: 31290203
[TBL] [Abstract][Full Text] [Related]
3. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
[TBL] [Abstract][Full Text] [Related]
4. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
5. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
[TBL] [Abstract][Full Text] [Related]
6. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
Thein KZ; Htut TW; Ball S; Swarup S; Sultan A; Oo TH
Breast Cancer Res Treat; 2020 Sep; 183(2):479-487. PubMed ID: 32647939
[TBL] [Abstract][Full Text] [Related]
8. Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer.
Graff SL; Yan F; Abdou Y
Clin Breast Cancer; 2023 Oct; 23(7):e380-e393. PubMed ID: 37407378
[TBL] [Abstract][Full Text] [Related]
9. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
[TBL] [Abstract][Full Text] [Related]
11. Evolving standards of care and new challenges in the management of HER2-positive breast cancer.
Choong GM; Cullen GD; O'Sullivan CC
CA Cancer J Clin; 2020 Sep; 70(5):355-374. PubMed ID: 32813307
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.
Kotecki N; Gombos A; Awada A
Expert Rev Anticancer Ther; 2019 Jun; 19(6):447-454. PubMed ID: 31082272
[No Abstract] [Full Text] [Related]
13. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.
Agostinetto E; Vian L; Caparica R; Bruzzone M; Ceppi M; Lambertini M; Pondé N; de Azambuja E
ESMO Open; 2021 Apr; 6(2):100091. PubMed ID: 33743330
[TBL] [Abstract][Full Text] [Related]
16. The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC.
Twelves C; Bartsch R; Ben-Baruch NE; Borstnar S; Dirix L; Tesarova P; Timcheva C; Zhukova L; Pivot X
Clin Breast Cancer; 2022 Apr; 22(3):223-234. PubMed ID: 34844889
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
[TBL] [Abstract][Full Text] [Related]
18. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.
Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A
Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705
[TBL] [Abstract][Full Text] [Related]
19. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
20. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
